T-follicular helper (TFH) lymphoma is a blood cancer subgroup that continues to demonstrate a generally poor prognosis, with no standard treatment established to date. Although specific genetic mutations are frequently observed in this disease, the association between genomic abnormalities and clinical features and prognosis remains unclear.
This article was originally published on MedicalXpress.com